TrialBMC nephrology2014

Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial.

Pablo Ureña-Torres et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.